Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: Results of myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial Meeting Abstract
| Authors: | Mesa, R. A.; Kosiorek, H. E.; Mascarenhas, J.; Prchal, J. T.; Rambaldi, A.; Berenzon, D.; Yacoub, A.; Harrison, C. N.; McMullin, M. F.; Vannucchi, A. M.; Ewing, J.; O'Connell, C. L.; Kiladjian, J. J.; Mead, A. J.; Winton, E. F.; Leibowitz, D. S.; De Stefano, V.; Arcasoy, M. O.; Kessler, C. M.; Catchatourian, R.; Rondelli, D.; Silver, R. T.; Bacigalupo, A.; Nagler, A.; Kremyanskaya, M.; Sandy, L.; Salama, M. E.; Najfeld, V.; Tripodi, J.; Weinberg, R. S.; Rampal, R. K.; Hoffman, R.; Dueck, A. C. |
| Abstract Title: | Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: Results of myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454842800201 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-111929 |
| Notes: | Meeting Abstract: 3032 -- Source: Wos |
